When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think…
The startup specializes in “non-invasive” “mind-reading” tech—a kind of neural data collection that, its CEO hopes, will have all sorts of consumer applications.